Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Nvidia Unveils Rubin Platform to Power Next Wave of AI Infrastructure 
BTIG Initiates Buy on SoftBank as AI and Robotics Strategy Gains Momentum 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Jollibee Plans U.S. Listing for International Business, Shares Rally 
SGH’s A$13.15 Billion BlueScope Bid Sparks Steel Sector Shake-Up and Share Price Surge 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
FDA Limits Regulation of Wearable Devices and Wellness Software, Boosting Health Tech Industry 
Intel Unveils Panther Lake AI Laptop Chips at CES 2025, Marking Major 18A Manufacturing Milestone 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
Newmont Goldcorp Expects Lower Q1 2026 Gold Output After Western Australia Bushfire 
Embraer Boosts Aircraft Deliveries in Q4 2025, Signaling Strong Growth Into 2026 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
SEATTLE, Oct. 24, 2017 -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Scott D. Myers, President and Chief Executive Officer, will participate in two panel discussions in the month of November.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/02938d7b-513e-467d-b9af-44a422fc2a16
November 7-8, 2017
Boston Biotech Conferences NY/NJ CEO, Apella at Alexandria Center, NY, NY
Panel: State of the Markets: Biotech and Pharma
More information on the conference can be found at http://bbbiotechconference.com/ceo-meetings.php
November 13-14, 2017
YJP CEO Europe Forum in Berlin will feature a Healthcare Innovation Symposium
Panel: Transitioning from an R&D Company to a Commercial Venture
More information on YJP and this meeting can be found at http://access.yjp.org/e/er4ka_4
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Its lead product candidate, tucatinib, is an investigational oral, selective small molecule kinase inhibitor that is highly selective for HER2 and the Company’s lead product in development for the treatment of HER2 overexpressing cancers. Cascadian Therapeutics is conducting a randomized, double-blind, controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo, each in combination with capecitabine and trastuzumab, in patients with locally advanced or metastatic HER2+ breast cancer with and without brain metastases, who have previously been treated with trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at www.HER2CLIMB.com or www.clinicaltrials.gov. For more information, please visit www.cascadianrx.com.
Investor and Media Contact:
Monique Greer
Cascadian Therapeutics
206-801-2107
[email protected]
